Skip to main content
Shenzhen Chipscreen Biosciences Co., Ltd. logo

Shenzhen Chipscreen Biosciences Co., Ltd. — Investor Relations & Filings

Ticker · 688321 ISIN · CNE100003LW0 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 967 across all filing types
Latest filing 2022-05-18 Capital/Financing Update
Country CN China
Listing Shanghai Stock Exchange 688321

About Shenzhen Chipscreen Biosciences Co., Ltd.

https://www.chipscreen.com/en/

Shenzhen Chipscreen Biosciences Co., Ltd. specializes in the discovery and development of original small molecule innovative drugs. The company leverages its proprietary chemical genomics-based drug discovery and early evaluation platform to address unmet medical needs in oncology, metabolic diseases, and autoimmune disorders. Its portfolio includes Chidamide (Epidaza), a selective histone deacetylase (HDAC) inhibitor approved for peripheral T-cell lymphoma and advanced breast cancer, and Chiglitazar (Bilessyl), a novel PPAR pan-agonist for type 2 diabetes. Chipscreen Biosciences maintains an integrated R&D system covering drug discovery, clinical development, and commercialization, focusing on molecular mechanisms and translational medicine to provide novel therapeutic solutions.

Recent filings

Filing Released Lang Actions
关于向不特定对象发行可转债的审核中心意见落实函回复的提示性公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement by Shenzhen Microchip Biotechnology Co., Ltd. regarding the response to feedback on the registration process for issuing convertible bonds to unspecified investors. It mentions regulatory bodies such as the Shanghai Stock Exchange and the China Securities Regulatory Commission. The content focuses on the company's reply to regulatory feedback and the status of the bond issuance registration, indicating it is an update on financing activities rather than a full financial report. The document length is short (681 characters), and it does not contain financial statements or detailed financial data. Therefore, it is best classified as a Capital/Financing Update (CAP).
2022-05-18 Chinese
关于深圳微芯生物科技股份有限公司向不特定对象发行可转换公司债券申请文件的发行注册环节反馈意见回复的专项说明
Audit Report / Information Classification · 100% confidence The document is a detailed audit report by KPMG Huazhen CPA firm on the financial statements of Shenzhen Microcore Biotech Co., Ltd. for the years ending 2019, 2020, and 2021. It includes extensive financial data, audit procedures, and explanations regarding revenue, profit, expenses, and accounting policies. The document references audit opinions, internal control audits, and compliance with accounting standards. It is not a full annual report but a standalone audit report related to a convertible bond issuance registration process. The length (15,000 characters) and detailed financial analysis confirm it is not a brief announcement or certification. Therefore, the document fits the category of Audit Report / Information (AR). FY 2021
2022-05-18 Chinese
关于变更监事暨提名监事候选人的公告
Board/Management Information Classification · 100% confidence The document is an announcement regarding the resignation of a supervisory board member and the nomination of a new candidate for the supervisory board. It details the resignation, the legal and procedural context, and the candidate's qualifications. There is no financial data, no mention of financial results, no report publication, or regulatory certification. The content focuses on changes in the company's supervisory board, which is part of the company's board/management information. Therefore, the document fits the category of Board/Management Information (MANG). The document length is short and it is not a report or announcement of a report publication, so it is not RPA or RNS.
2022-05-13 Chinese
关于召开2022年第一次临时股东大会的通知
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a notice about convening the 2022 first extraordinary general meeting of shareholders for Shenzhen Microchip Biotechnology Co., Ltd. It includes details about the meeting date, voting methods, agenda items, and proxy authorization forms. There is no financial data, earnings information, or report content. It is an announcement related to a shareholder meeting, specifically a notice for an extraordinary general meeting (EGM). This fits the category of Proxy Solicitation & Information Statement (PSI), as it provides materials sent to shareholders to inform and request votes for the meeting.
2022-05-13 Chinese
第二届监事会第十次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a formal announcement of a supervisory board meeting resolution regarding the resignation and replacement of a non-employee representative supervisor. It details the meeting attendance, the agenda, the voting results, and references a related announcement on the stock exchange website. There is no financial data, no report publication, no voting results from a shareholder meeting, and no executive or board member changes at the director level. The document is a regulatory announcement about board supervisory changes, but not a full management or board change announcement (which usually involves directors or senior management). It fits best as a Regulatory Filing (RNS) because it is a formal compliance announcement that does not fit other specific categories like MANG (board/management changes) or DVA (voting results). The document length is short and it is an announcement, not a full report or transcript.
2022-05-13 Chinese
深圳微芯生物科技股份有限公司向不特定对象发行可转换公司债券发行注册环节反馈意见落实函
Regulatory Filings Classification · 95% confidence The document is a formal communication from the Shanghai Stock Exchange to Shenzhen Microchip Biotechnology Co., Ltd. and Anxin Securities Co., Ltd. regarding feedback on the registration process for a listing on the Science and Technology Innovation Board (科创板). It includes detailed questions and requests for explanations about financial performance, accounting policies, and compliance with accounting standards. The document is a regulatory feedback letter related to the registration and listing process, not a financial report or earnings release. It does not contain financial statements or substantive financial data but rather requests clarifications and updates. The document length is short (1352 characters), and it is clearly a regulatory communication. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements and compliance documents that do not fit other categories.
2022-05-10 Chinese

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.